Most researchers searching for CJC-1295 in Cedro rapidly learn that local retail options are essentially nonexistent. The practical takeaway for Cedro researchers: sourcing CJC-1295 comes down completely to vendor quality evaluation, not geography — and the evaluation methodology is the same regardless of where you are. Separating properly characterised CJC-1295 from the rest of the market depends on three things: an HPLC chromatogram documenting ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. What follows is a practical research guide built specifically around CJC-1295, covering everything a Cedro researcher needs to evaluate quality systematically.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Cedro comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
Evaluating CJC-1295 vendors requires starting from the COA: locate the batch-specific certificate prior to buying, not after. The HPLC chromatogram is the most important document in the COA: it should show a dominant main peak representing CJC-1295, with negligible secondary peaks representing impurities — purity should be stated as ≥98%. Positive vendor signals beyond COA quality: documented vendor history spanning multiple years, knowledgeable support capable of explaining COA data, and cold chain packaging that protects product integrity. Store lyophilised CJC-1295 at minus 20 degrees Celsius until ready to use; reconstitute only the amount needed for the near-term protocol and return unused portion to the freezer.
Order CJC-1295 — ships to Cedro
COA-verified · International tracking · Research grade
All use of CJC-1295 in Cedro or anywhere must be research use only — this compound is not approved for clinical human use, and all handling should adhere to research compound handling standards. Storage requirements for CJC-1295: lyophilised powder at minus 20°C, reconstituted solution refrigerated at 2-8°C and finished within 30 days of reconstitution; reconstitute only with bac water. Endotoxin testing in the CJC-1295 COA is not optional — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at trace quantities, and no cost saving makes omitting this acceptable. For any individual considering CJC-1295 outside a formal research context: consult a qualified physician — this compound is not a licensed human medication and its risk profile is not equivalent to approved medications.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
